Organogenesis plans rolling BLA submission for ReNu by year-end

CANTON, Mass. - Organogenesis Holdings Inc. (NASDAQ:ORGO) announced Monday it completed a Type-B meeting with the Food and Drug Administration, receiving confirmation to initiate a rolling Biologics License Application for its ReNu product before the end of December. The positive regulatory news comes as the stock trades near its 52-week low of $2.21, with shares down 57% year-to-date despite analysts setting a price target of $8, suggesting significant upside potential.